

**Supplementary Table 1. Demographic, clinical and treatment details of youth with systemic lupus erythematosus (n=115)**

Variable	Value
Female sex	99 (86.1)
Age at enrollment (yr)	14.3±3.6
Age at diagnosis (yr)	11.8±2.9
Kidney involvement	82 (71.3)
Proliferative lupus nephritis	64 (78.0)
Estimated GFR (mL/min/1.73 m <sup>2</sup> )	105.3±32.1
Advanced CKD	14 (12.2)
Comorbidities	
None	14 (12.2)
Hypertension	82 (71.3)
Vitamin D deficiency	19 (16.5)
Anemia	14 (12.2)
Endocrine and metabolism	14 (12.2)
Nervous system	8 (7.0)
Other <sup>a)</sup>	15 (13.0)
ACEI treatment	93 (80.9)
Immunosuppressive therapy	
Prednisolone	113 (98.3)
Hydroxychloroquine	103 (89.6)
Cyclophosphamide	54 (47.0)
Mycophenolate mofetil	84 (73.0)

Values are presented as number (%) or mean±standard deviation.  
 GFR, glomerular filtration rate; CKD, chronic kidney disease; ACEI, angiotensin converting enzyme inhibitor.

<sup>a)</sup>Cataract, thromboembolism, avascular necrosis, and tuberculosis.